InnoCare Pharma Limited()
(9969)
625,4041,043,033198,199217,938(438,611)(298,463)(639,139)(721,584)(181,556)(139,815)(291,167)(1,271)(893,727)(66,679) (473,691)2,630
214.7
163.6%565.9
625.4
1,043.0417.6
776.0
217.9
198.2
(i)57.1(ii)0.07
8.48.5(iii)
16.329.946.2
(iv)135.11.8
136.9
1,161.11,550.5(i)
57.1290.6(ii)304.5115.4
419.9273.0
2.5(iii)
298.5140.1
438.6
66.7893.7
2.6473.7
(893,727) (66,679)
290,559 (57,135)129,477126,444(473,691)2,630
BTBT
MSII12
BTKII12Gd+T180QD92.1%(p=0.0006)SLEIIa
SLESRI–4
EULARCDESLE
IIb
ITPIIPoC50 x 10
L
36.4%33125040%156
ICP-332ICP-3322TYK2T
IIPK/PDJAK-2AEADIIICP-488ICP-488TYK2TYK2JH2
IL-23IL12IIFNICP-
ISADMAD
ICP-248ICP-490ICP-B02TafasitamabNHLMM
BDLBCLNHL
?
?
BTK
565.9214.7164%CSCO? NMPA
MZLNDA? CLL/SLL
III
? MCLII
NDA? -1PD-1
EHANHLDLBCL
? MCDBDLBCL
III
R-CHOPR-CHOP
R-CHOPMCD DLBCL
ASCO14
CRR75%66.67%
ICP-B04TafasitamabCD19(Minjuvi
?
)? TafasitamabDLBCL
ASCTDLBCLTafasitamabCSCOASCTDLBCL
? TafasitamabNMPA
ASCTBDLBCLTafasitamabDLBCLTafasitamab
DLBCL
ICP-B02 (CM355)? ICP-B02CD20xCD3I
ICP-B02BICP-B02SCINDCDEMMICP-490? ICP-490
INDCDEI
ICP-248
? ICP-248B2BCL-2
BCL-2ICP-248INDCDE
I
ICP-192ICP-
ICP-192 (Gunagratinib)
ASCO-GIGunagratinibCCAIIaICP-192GunagratinibFGFR2
CCAFGFR(52.9%)CCAICP-192
I/II
ICP-723 (Zurletrectinib)I20DLTII
RP2D8NTRK75%ORR129 PR
RP2D77.8%ORR97 PR12
INDCDE
CDE
ICP-189ICP-B05ICP-033
ICP-189
ICP-189SHP2
IaICP-18940DLTPKICP-18920
1PRICP-B05 (CM369)ICP-B05C-C8CCR8INDI
ICP-B05
Tafasitamab
?
163.6%DLBCLCD19TafasitamabBLA
? 13
PoCMSITP
1L DLBCL-MCD1L CLL/SLL1LMCLMZLWMMCL
ICP-192SLEPoCMSPoC
ITPIIPoCBTKi? TYK2ICP-332
ICP-488CD3xCD20BCL-2E3 LigaseCCR8SHP2
?
CMC
?
1.02.0
BTMultiple Sclerosis International FederationMSIF280MSFrost & Sullivan
MS230317BTKBMSBTK
MSBBBMSBTK
IIMS
MSBTK
BSLEIIaSLEBTK
ITPNMOSDII
TICP-332ICP-488TADSLELNIBD
BICP-332ICP-488T
ICP-248ICP-490ICP-B02Tafasitamab
MMNHL
?BMZLWMCLL/SLLMCLMCDDLBCL
MCLNHL
ICP-192ICP-723ICP-189ICP-B05ICP-033
IND
ICP-B02ICP-B05Tafasitamab
?
BTKCLL/SLLMCL
625.4
565.9163.6%250
1,5006,000
DOT
?BTK?
CSCOCLL/SLLMCLBTKDLBCLpCNSL
NDA
IND Enabling
PH3PHIaPH2*
FiledPHIbPH2**
Market
ICP-022/Orelabrutinib
BTKr/r WMr/r CLL/SLLr/r MCLr/r MZL
ICP-B02CD3 x CD20
ICP-248BCL-2
ICP-490E3Ligase
1L:CLL/SLL
Tafa+ LEN, r/r DLBCLr/r MCL1L:MCL
ICP-B04/
Tafasitamab
CD191L:MCD DLBCL
HKTafa+ LEN + OrelaNHL
CHN,SG
CHN
CCR8ICP-B05Hemato-oncologyNHL/ALLMM/DLBCL
202012252020122520228NDANMPA2022NDANMPA2022
202212202332022720233
NDA
IND Enabling
PH3PHIaPH2*
FiledPHIbPH2**
Market
ICP-B05
pan-FGFRpan-TRK
ICP-192/Gunagratinib
ICP-723/Zurletrectinib
VEGFR, DDR1ICP-033
SHP2ICP-189
CCR8
BTKTYK2 –JH1TYK2 –JH2
ICP-022/OrelabrutinibICP-332ICP-488
NTRK
IIPoC
20232
INDFDA
BTBT
MSITPNMOSD
CSU
ICP-332 (TYK2i-JH1)ICP-488 (TYK2i-JH2)
ADPsoriasisIBDLNCDUCSLE
T
(BTKi)B
NMOSD:
ITP:
CSU:
SLE:
AD:
IBD:
LN:
CD:
UC:
IIaIIb
IIPoCIIPoCIIMS:
III
(CNS)B
SLEIIaSLEBTKIIbMSIIPoCITPNMOSDIICSU
TTYK2ICP-332ICP-488TADSLEIBDLNCDUC
BICP-332ICP-488T
BBTKTECB
BCRBBTKBTK
MS
MSIIIIRMSOLERMS1:1:1:1
450QD50BID80QDOLE
GdE T1 MRI12GdET1MRI
13612Gd+T150QD71.1%(p=0.0238)50BID80.8%(p=0.0032)80
QD92.1%(p=0.0006)
12Gd+T1
PlaceboN=34
Orela 50mg QDN=33
Orela 50mg BIDN=34
Orela 80mg QDN=35
71.1%,
P=0.0238
80.8%,
P=0.0032
92.1%,
P=0.0006
(95% CI?)
1CIQD=BID=pPearson
RMSII
InnoCare80mg QD92.1%Cumulative Gd+lesionsatWk12Placebo-controlled(N = 136), 24Wk + ext
Sano60mg QD85%
(2)Dose-response for Gd+lesions at Wk12Placebo-controlled for 4Wk, with12Wk cross-over (N=130), 16Wk + ext
MerckKGaA75mg qd(56% at75mg bid)70%
(3)Cumulative Gd+ lesions at Wk12,
16, 20, and 24Placebo-controlled + open label DMF (N =
267),24Wk + ext
BTK
Roche600mg q6mo89%
(4)Cumulative Gd+ lesions at
Wk12, 16, 20, and 24Placebo-controlled + Inf-b1a referencearm (N=218), 24Wk + ext
Novartis60mg q12w65%
(5)(6)
91%
(7)
Cumulative Gd+ lesions at
Wk 12Placebo-controlled (N=231), 24Wk +
ext
Novartis2mg qd72%
(8)Dose-response for CUAL at
3 moPlacebo-controlled, adaptive, doseranging
(N = 297), 6m + ext
Biogen240mg tid69%
(9)Cumulative Gd+ lesions at Wk12,
16, 20, and 24Placebo-controlled(N = 257),24Wk + ext
Novartis5mg qd61%
(10)
88% atmo. 6Cumulative Gd+ lesions
monthly for 6 monthsPlacebo-controlled (N = 281), 6m + ext
Sano14mg qd61%
(11)
# of CUAL per MRI scanPlacebo-controlled (N = 179), 36Wk + ext
T1
BTKTolebrutinibBTK
CD20CD20
S1PRS1PR
(1)
1 www.clinicaltrials.gov; (2)Sanofi’s R&D held on April 23, 2020;(3) MontalbanX, et al. NEngl J Med 2019; 380:2406-2417;(4) KapposL, et al. Lancet 2011;378:1779-87 (5) Bar-OrA. et al, Neurology 2018;90:e1805-e1814; (6)Endpoint with full data (0-12 Wks) (7) Posthoc data (4-12 wks);(8) Selmaj K, et al Lancet Neurol 2013;12:756-767;(9) Kappos L, et al.Lancet 2008;372(9648):1463-72;(10) Kappos L, et al. N Engl J Med 2006; 355:1124-40;(11)O’Connor P, et al. Neurology 2006;66(6)
MSMS
CNSPKBBBMS
PKBTKevobrutinibtolebrutinibevobrutinibtolebrutinibCNS
plasmacyte
B
B
B
B
T
T
BTK+
(CNS)
AQP4
T
MoG
TT
BTK(mg)
CSF Conc. ~2h(ng/mL)
Orelabrutinib150 QD
31.3
InnoCareEvobrutinibMerck KGaA75 BID
3.21
Sano120 QD
1.87
Tolebrutinib
1 doi: 10.1016/j.msard.2021.1030002 Multiple Sclerosis and Related Disorders 51 (2021) 103001 Topic: Advances in therapy in
MS; doi: 10.1016/j.msard.2021.103001
EAEMSMOGEAE
EAE
EAEMS
MSDMTFDABiolato M, Bianco A, Lucchini M, Gasbarrini A, Mirabella M, Grieco A. TheDisease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and LiverInjury: A Narrative Review. CNS Drugs . 2021 Aug;35(8):861-880
26MS2624
HBV
DMTBiolato M, Bianco A, LucchiniM, Gasbarrini A, Mirabella M, Grieco A. The Disease-Modifying Therapies ofRelapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review. CNSDrugs. 2021 Aug;35(8):861-880ALT
ALTβ136
136912
C
62C
BC
AALTFDA
IIMSIBICFFDAiDMCiHACFDA
FDA
MS
MS
8.125
MS
BMSIIMSOLE
MSBTK
SLEBTKBCRBSLE
SLEII
EULARSLE1:1:1:1125080100
II
508010012SRI-4
35.7%50.0%61.5%64.3%
GC3C4
IIaSLE
IIbSLESLE
SLE1:1:1255048SRI-4
SRI-6C3C4dsNDA
35.7%
50.0%
61.5%
64.3%
14.3%
25.8%
28.6%
(n=55)
0%10%20%30%40%50%60%70%80%90%
| 100% |
(N=14)
(N=14)
(N=13)
(N=14)
SLEBTKevobrutinibfenebrutinib
Ringheim, G. E., Wampole, M., & Oberoi, K. (2021) Frontiers in Immunology, 12,662223SLEBTK
SLE
ITPITPITP
TBTKBITPB
BTKITPITP
ITPIIIIITP
III
×109/L2
22GCIVIG5075.0%8636.4%331240%15650IIITP
NMOSDNMOSD
45-650.445/100,000
4.71:1
NMOSDB4AQP4 IgG80%AQP4 IgGBTKB
BBTKBTKBTKNMOSD
IITII
IIT
T–TYK2ICP-332
ICP-332TYK2TYK2JAKIL-12/IL-23IFNT17TH17TH1BADICP-332TYK2
400JAK2JAK
TYK2ICP-332
IBDPharma Intelligence
120.96-22.6%1.2-17.1%
ICP-332
CDEICP-332I
IIPK/PDJAK-2AE
ADII
I14ICP-332532040160QDPKPD8
ICP-3326280ICP-322ICP-3325320PKCmaxAUClast
14320160QDICP-332
ICP-488ICP-488TYK2JH2JH2TYK2
JH2TYK2ICP-488TYK2TYK2 JH2IL-23IL-12IIFNICP-488SLELNIBDICP-332ICP-488
TYK2I
136SADMADICP-488
ICP-248ICP-490ICP-B02Tafasitamab
NHLMM
DLBCLNMNHL(i)(ii)FDAEMACD19TafasitamabDLBCL(iii)
CD20xCD3BCL-2E3 Ligase(iv)
DLBCLTafasitamabBCL-2 E3 LigaseDLBCL
1L DLBCLMCDTafasitamab
DLBCL
ICP-248
ICP-B02
ICP-248
Orelabrutinib
TafasitamabICP-490
ICP-B05/CM369
ICP-490
OthersCMLALLAMLPTCL/CTCLDLBCLCNSLFLWMMZLMCLCLL/SLLOthersMM
NHL
850CLL/SLLMCL
CDE
MCLAE3
1L CLL/SLL
IIICLL/SLLIRCPFS
CLL/SLLIICLL/SLL15080CLL/SLL
4756.2%ORR93.8%CR30%
1.84DOR
PFS48DORPFS
56.2%52.7%CLL/SLL
BTKCR
AECLL/SLLGazyvaFCR
BTKi
7.1611.073PR/PR-LSDORR75%DCR100%
BTKiCLL/CLL
1L MCL
IIIR-CHOPR-CHOPIRCiwNHLPFS
MCLIIMCLDORPFSOS106
39.43
83%87.8%CT
36.8%
MCLTRAE
MCLIIFDABTD
MCL
WMWMBMIgMBTKWM
MYD88L265PBTKBTK
WMIRCMRRMRRORRDOMRPFSOS
24.90MRR80.9%ORR91.5%12DOMR84.9%12PFS81.2%PFS
AE
(Lancet eClinicalmedicine)MZLII150MZL111
90MZL90MZL53PR43CR10IRCORR58.9%95% CI48.069.2DOR34.395% CINANAPFSOSIRC12PFSOS
82.8%91%ibrutinibMZLORRCRPFSOSCDECDE
MZLBTKNHLDLBCL
1L DLBCL-MCD
DLBCLNHL100
MCD1L DLBCL
IIIR-CHOPR-CHOPMCDDLBCLIRCPFS45
40%DLBCL
R-CHOP+XMCDB
NF-KBBTK
TITKCD20NKADCC
R-CHOPMCDDLBCL
ASCOR-CHOPMCD DLBCL14MCD DLBCL
1508R-CHOPR-EPOCH6RICER-CHOPR2CRR75%66.67%
MCDDLBCL
MCDDLBCL
Tafasitamab (CD19)ICP-B02 (CD3xCD20)ICP-490E3DLBCL
pCNSLpCNSL
pCNSLND pCNSLCNSL
pCNSLORRCR88.9%100%53.9%61.8%ND pCNSL
PFSmPFS6PFS63.6%100%
60%CNSLORR60%
86.7%mPFS9.83
mPFS
BCRMYD88
MOABBB150
21.6BBB58.6%
pCNSL
BTKCD20
BTKBBCRCD20CDCADCC/ADCPBTK2IL-2-ITKNK
ADCC(Mol Ther Oncolytics 21: 158-1702021
BTKBTKB
ADCCMol TherOncolytics 21:158-1702021Gazyva
ADCCADCPCD20CD19Tafasitamab
CD20Gazyva(obinutuzumab)ADCCADCP
BTK
CD20/CD19B
CD20GazyvaBTafasitamabNHLIIICP-B04 (Tafasitamab)
CSCOTafasitamab
CSCOASCTDLBCLDLBCL
CHOP
TafasitamabTafasitamabTafasitamabTafasitamabNMPA
2CRTafasitamab
18TafasitamabDLBCL
TafasitamabDLBCLII
IITafasitamabDLBCL
ORRIRCDCRDoRPFSTTPTTROS
TafasitamabBDLBCLNHL40%Frost & Sullivan
DLBCL59119NHL/DLBCLTafasitamab
IncyteTafasitamabFcCD19TafasitamabFDA
DLBCLDLBCLASCTIIL-MIND
57.5% ORR(40% CR)33.5mOS43.9mDoRTafasitamab
CD19B-NHLB-NHLRE-MIND2R2Tafasitamab
Incyte35Incyte
82.5
Tafasitamab
Incyte
BTKTafasitamab
TafasitamabBTafasitamabADCCADCPBCD19
IncyteTafasitamab
ICP-B02 (CM355)ICP-B02
CD20xCD3
TDCCICP-B02
50%ICP-B0250%
I/IIICP-B02NHLPKIICP-B02
DLT53+3
DLTICP-B02BICP-B02SCINDCDE
MMICP-490ICP-490CRBN E3TPD
CRL4CRBN-E3ICP-490IKZF1IkarosIKZF3AiolosICP-490
CRBN E3AiolosIkarosICP-490MMBDLBCLICP-490CRNBICP-490ADCCCD38daratumumabICP-490DLBCLICP-490MM
IMiDMMNHL
INDCDEI
ICP-248ICP-248B2BCL-2BCL-2BCL-2
BCL-2ICP-248ICP-248BCL-2ICP-248ALLAMLFLCLLDLBCLBCL-210%20ICP-248
ICP-248INDCDEIIICP-248BCLL/SLLMCLICP-248ICP-248CLL/SLL
ICP-192ICP-723
ICP-189ICP-B05ICP-033
ICP-192 (Gunagratinib)
ORR52.9%DCR 94.1%
ICP-723 (Zurletrectinib)
NTRK8ORR75%
ICP-189
SHP-2
ICP-B05
CCR8
EGFRiRTKiKRASiVEGFi
ICICDK4/6i
RAFiMEKiPD-1/PD-L 1
FGFRICP-192TRKICP-723SHP2CCR8ICP-189ICP-B05ICP-033
ICP-192 (Gunagratinib)Gunagratinib
FGFRFGFR
7.1%
FGFR
GunagratinibFGFR
FGFRGunagratinibFGFR
GunagratinibCCAIIaICP-19218CCA17
5.57ORR52.9%17
9DCR94.1%1716mPFS
6.9395% CI5.42TRAE
FGFRGunagratinibCCAFGR2
(52.9%)GunagratinibI/II
IIIIORR44.4%94DCR88.9%98ICP-723 (Zurletrectinib)
ICP-723TRK
TRKTRKNTRKTRKTRKICP-723TRKA/B/CTRKAG595RG667CICP-723TRKICP-723ROS1ROS1
TRKTRKATRKBTRKC
NTRK1NTRK2NTRK3TRK
NTRKNTRKNTRKC-Ros1(ROS1)
NSCLCROS1NSCLC
I/IIICP-723NTRK/ROS1PK
ASCOI/IIIIIIIINTRKROS1
TRKROS1I24DLTII
RP2D8NTRK75% ORR129 PR877.8% ORR97 PR6ROS1ORR50%
4PRDLT12INDCDE
CDEEoP2
ICP-189
ICP-189SHP2ICP-189SHP2RAS-MAPK
PD-1SHP2
ICP-189ICP-189
EGFRKRASMEKPD-1
IaICP-18940DLT3TRAESAEICP-189
PRICP-189PKICP-189
IbICP-189EGFRPD-1
ICP-189INDFDA
ICP-B05 (CM369)ICP-B05C-C8CCR8CCR8TMET
TregsCM369TregsCCR8ADCC
TregsTMECM369T
ICP-B05INDCDE
IICP-B05
ICP-B05
ICP-033ICP-0331DDR1VEGFR
ICP-033ICP-033
ICP-033I
PROTACXDC
50,000GMP
NMPABTK
30,000
CMC
70,381
29.19
MSBTK
%%566,75590.6214,66620.658,6499.452,4045.0
––775,96374.4
625,404100.01,043,033100.0
1,043.0
625.4
352.1164.0%
566.8
776.0
%%471,17097.8191,00819.5
10,8372.210,3951.1
––775,96379.4
482,007100.0977,366100.0
977.493.7%
482.077.1%
217.9
198.2
(i)57.1(ii)0.07
8.48.5(iii)
16.329.946.2(iv)135.11.8
136.9
721.6
639.1
%%2,4900.4273,02637.8 196,82630.8167,58923.2
223,09534.9136,92319.058,1649.139,4285.543,0836.721,8373.0115,48118.182,78111.5
639,139100.0721,584100.0
(i) 273.0270.5
2.5
(ii) 167.629.2
196.8
(iii) 136.986.2223.1(iv) 39.418.858.2(v) 21.821.343.1(vi) 82.8
32.7115.5
139.8
181.6(i)
47.078.0(ii)
3.6
11.3(iii)1.4
6.9(iv)9.2
15.8
%%78,00843.046,96433.634,35718.943,01730.835,15919.435,56325.411,2976.23,6372.66,8953.81,3921.015,8408.79,2426.6
181,556100.0139,815100.0
298.5
438.6
(i)126.5
219.4(ii)100.7
143.1
%%219,42250.0126,46242.4143,10532.6100,71233.736,9568.543,99914.739,1288.927,2909.2
438,611100.0298,463100.0
57.1
290.6
51.0
3.4
9.7
0.6
2.6
17.0
46.6
127,82545,27395,344116,14565,3229,918313,290317,0598,697,9275,928,716
9,299,7086,417,111
118,59784,6024,2426,831727,552204,8867,75712,64720,11220,3361,197,168–
2,075,428329,302
7,224,2806,087,809
7,224.38,697.9127.8
95.3
313.3
727.6118.61,197.2
127,82245,273
3–
127,82545,273
116.195.3
16.316.3
33,55737,53244,98741,363
–16,34012,14717,3624,6533,548
95,344116,145
313.3
317.1304.7
9.965.3
111,18684,4597,335121
6617
118,59784,602
204.9
727.6
(i)47.0
104.1(ii)
41.4
57.0(iii)
33.17.6(iv)23.0
51.4(v)
459.5
104,05046,95657,01441,40632,58037,3607,62833,07051,39123,024
–20,000459,517–15,3723,070
727,552204,886
20,11220,336459,517–1,197,168–
35,43947,442287,76137,693
–1,200,564
1,999,9971,306,035
1,306.02,000.0
136.3
286.0
430.1
653.2
136.0
284.1
34.2
41.3SAP
21.4
11.7
51.0
28.0
4.519.5
1,197.2
204.9
727.6
84.6
118.6
5,928.78,697.9
8.95
250,324,0000.0000023,8832,240.4
H.10
37,548,00015%
322.59
210,508,00014.45
264,648,2170.000002
11.03
2,778.82
9,011.26,550.5
(i)8.5(ii)6.6
100%18.8%17%
1,197.2
287.8
459.5
163.4
171712-1716
(i)(ii)
–(i)
(ii)3.05
(iii)62216
–
––
13.51(2)
–
13.51B(1)
C.2.1
(i)(ii)
(iii)
3.10(2)3.21
2,415.671,260.2
52.2%
50%1,207,835853,114441,116411,998
40%
*
966,268812,054115,853696,201
10%
241,56763,66616,35047,316
2,415,6701,728,834573,3191,155,515
*
(i)(ii)
Gaoling Fund L.P.YHG Investment L.P.Vivo Opportunity Fund, L.P.210,508,000
16.33%14.04%
14.45421.023,041.44210,508,000
14.45
15.723,041.843,041.44
3,041,4401,704,4981,336,942
2,919.07140.25
2,778.82
545.7
1,494,220.6–1,494,220.6
116,146.6–116,146.6
273,851.4–273,851.4
60,952.3–60,952.3
833,644.7–833,644.7
2,778,815.6–2,778,815.6
625,4041,043,033(143,397)(65,667)
482,007977,366
198,199217,938(438,611)(298,463)(639,139)(721,584)(181,556)(139,815)(291,167)(1,271)3,396(51,014)
(100)(32)
(9,711)(604)
(17,045)(2,642)(893,727)(20,121)
–(46,558)(893,727)(66,679)
(886,593)(64,545) (7,134)(2,134)
(893,727)(66,679)
0.600.05
(893,727)(66,679)
429,445(89,453)429,445(89,453)(464,282)(156,132)
(457,148)(153,998) (7,134)(2,134)
(464,282)(156,132)
653,163430,081284,103135,9993,1253,12541,30534,16611,71221,423
–304,67528,04250,9511,021,450980,42065,3229,918
127,82545,27395,344116,145313,290317,0598,697,9275,928,7169,299,7086,417,111
118,59784,602
4,2426,831727,552204,8867,75712,64720,11220,3361,197,168–2,075,428329,3027,224,2806,087,8098,245,7307,068,229
–1,200,56435,43947,442287,76137,693278,203123,611601,4031,409,3107,644,3275,658,919
23197,597,0785,604,5407,597,1015,604,559
47,22654,3607,644,3275,658,919
1.
Ogier Global (Cayman)Limited, 89 Nexus Way, Camana Bay, Grand Cayman KY1-9009 Cayman Islands
1100%–1–100%InnoCare Pharma Inc.10,000,000–100%InnoCare Pharma Australia Pty Ltd.10–100%
(a)
80,000,000–100% 10,000,000–100%
49,225,100–91.08%
4,000,000–100% 1,000,000,000–93%
(a)
30,000,000–100%(a)
2.1
(a)(b)(c)
(i)(ii)(iii)(i)
(ii)(iii)
2.2
(a) 3
3721
(b) 16
(c) 3737
(d)
1916
? 9
2.3
1, 5
2, 4
10281028
1212
7,852,0007,877,000
3.
(a)
568,035216,06657,369826,967625,4041,043,033
(b)
1,020,695674,729
7551,0161,021,450675,745
10%
A*826,967B224,090*C101,386*D81,916*
407,392826,967
*
10%4.
625,4041,043,033
(a)
–775,963566,755214,66657,36951,003
1,2801,401
625,4041,043,033
568,035216,06657,369826,967
625,4041,043,033
568,035992,03057,36951,003
625,4041,043,033
Biogen Inc.
MSBTK
7,797–(b)
3090
17,7837,797 –17,783
17,78325,580
46,15916,257136,914135,1358,48670
832,608191,642154,070
6,5576,733
–57,135198,199217,938
5.
16.5%
16.5%
2,000,0002,000,0008.25%
8.25%16.5%16. 5%
25%15%
15%15%25%
50,000,00025%26%50,000,000
30%30%
21%21%
–52,593–(6,035)–46,558
(893,727)(20,121)25%(223,432)(5,030)
97,15222,37065,183(23,565)(62,491)(56,802)
–(82,003)103,983134,18418,1484,7201,45791–52,593–46,558
1,511,700,000
6.
7.
(886,593)(64,545)
1,479,5651,366,261
8.
127,95745,304
(132)(31)
127,82545,273
127,82245,273
3–127,82545,273
31–10032
1––(1)13231
127,9570.10%132
45,3040.07%32
9.
111,18684,4597,335121
6617
118,59784,602
10.
MSBTK
(www.hkexnews.hk)(www.innocarepharma.com)
AD
ALLAMLAQP4 IgG4 ASH
BBBT
BBiogenBiogen Inc.BIIB
BTDBTKBTKCD20B CD20MS4A1
BCDCCDENMPA
CLLCNSL
9969
DLBCLB
DLT
EULARFGFR
FL
GMP
IBDICP-105ICP-192ICP-022
iDMCIL-2-2IL-5-5IL-12-12IL-23-23IND
IRCITKTITPiwNHLJAK
MCDB(DLBCL)
MYD88L265PCD79BMCDMCLB
MSMZLNDAMMOSD
NMPA
NRDLNTRKFGFR(FGFR)TRKPDPK
R/Rr/rR-CHOPRICE
264,648,217
SC
0.000002
SHP2RAS
SLESLLSRISLE
T
TTBNKTDCCTTRK
TYK22UC
U.S.
FDAFDA
VivoVivo Opportunity Fund, L.PVivo Capital VIII,
LLCWM